Literature DB >> 11117539

Factors predicting prognosis of epilepsy after presentation with seizures.

B K MacDonald1, A L Johnson, D M Goodridge, O C Cockerell, J W Sander, S D Shorvon.   

Abstract

The objective of this study was to identify the factors, at the time of diagnosis, that determine the prognosis for remission of epilepsy. A prospective community-based cohort study of 792 patients recruited at the time of their first diagnosis of epileptic seizures was undertaken; in those classified 6 months after presentation, the median follow-up period was 7.2 years (quartiles at 6.2 and 8.2 years) after presentation. We analyzed data from 6 months after the first identified seizure, which prompted the diagnosis of epilepsy, to allow us to factor in those aspects contingent on a diagnostic assessment Baseline clinical and demographic data were analyzed using the Cox proportional hazards regression model with remission of epilepsy for 1, 2, 3, and 5 years as outcome measures. The dominant clinical feature predicting remission was the number of seizures in the 6-month diagnostic assessment period. Thus, the chance of entering 1 year of remission by 6 years for a patient who had 2 seizures during this initial 6 months was 95%; for 5 years of remission, it was 47% as opposed to 75% for 1 year of remission and 24% for 5 years of remission if there had been 10 or more seizures during this period. The number of seizures in the early phase of epilepsy (here, taken as the first 6 months after presentation) is the single most important predictive factor for both early and long-term remission of seizures.

Entities:  

Mesh:

Year:  2000        PMID: 11117539

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  40 in total

1.  Honing in on risk factors for prolonged remission off medication by reducing heterogeneity.

Authors:  Dale C Hesdorffer
Journal:  Epilepsy Curr       Date:  2012-05       Impact factor: 7.500

2.  Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Maria Sudell; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-06-24

3.  New developments in antiepileptic drug resistance: an integrative view.

Authors:  Dieter Schmidt; Wolfgang Löscher
Journal:  Epilepsy Curr       Date:  2009 Mar-Apr       Impact factor: 7.500

4.  Intrinsic severity as a determinant of antiepileptic drug refractoriness.

Authors:  Michael A Rogawski; Michael R Johnson
Journal:  Epilepsy Curr       Date:  2008 Sep-Oct       Impact factor: 7.500

Review 5.  Phenobarbitone versus phenytoin monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nevitt; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2019-07-31

Review 6.  Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data.

Authors:  Sarah J Nevitt; Maria Sudell; Jennifer Weston; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2017-06-29

Review 7.  Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nolan; Maria Sudell; Catrin Tudur Smith; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2016-12-06

Review 8.  Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review.

Authors:  Sarah J Nolan; Anthony G Marson; Jennifer Weston; Catrin Tudur Smith
Journal:  Cochrane Database Syst Rev       Date:  2016-12-15

Review 9.  Seizures in alcohol-dependent patients: epidemiology, pathophysiology and management.

Authors:  Matti Hillbom; Ilkka Pieninkeroinen; Maurizio Leone
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 10.  Treatment strategies after a single seizure : rationale for immediate versus deferred treatment.

Authors:  Laura C Miller; Frank W Drislane
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.